Finnish team of researchers finds a mutation in a tumor of the jaw

A Finnish team of researchers was the first in the world to discover a gene mutation in ameloblastoma, which is a tumour of the jaw.

Ameloblastoma is an odontogenic tumour with a high tendency to recur after . Ameloblastoma is most often found in the posterior of the lower jaw. Ameoloblastomas are treated by surgery, often resulting in tissue deficiencies in the jaws as well as loss of several teeth. A suitable drug therapy could reduce the need for surgery and the recurrence of ameloblastoma, but finding such a treatment requires a better understanding of the pathogenesis of the tumour.

Researchers have been searching for the mutation that causes ameloblastoma for decades, and this mutation has now been found in a patient living in the eastern part of Finland. The core of the team making the discovery comprises researchers of the University of Turku and the University of Eastern Finland. According to the leaders of the team, Professor of Medical Biochemistry Klaus Elenius of the University of Turku, and Professor of Oral Diagnostic Sciences Kristiina Heikinheimo of the University of Eastern Finland, the finding is a scientific breakthrough. The significance of the finding is further emphasised by the fact that it has direct implications for treatment, because a targeted drug for the mutation in question already exists.

The findings were published in Journal of Pathology in March.

More information: Kari J Kurppa, Javier Catón, Peter R Morgan, Ari Ristimäki, Blandine Ruhin, Jari Kellokoski Klaus Elenius and Kristiina Heikinheimo. High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 2014; 232: 492–498.

add to favorites email to friend print save as pdf

Related Stories

Researchers identify new gene mutation associated with ALS

Apr 01, 2014

A research team led by investigators at the National Institute on Aging at the National Institutes of Health has discovered a new gene mutation associated with ALS, amyotrophic lateral sclerosis. The mutation is involved ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

55 minutes ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

10 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.